Abstract
The coexistence of autoimmune disorders (AD) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) has been widely recognized, although with distinct results regarding their prevalence and impact on the outcomes of the underlying hematological process. This study was aimed to analyze the prevalence, clinical characteristics, and outcomes of MDS with AD in a series of 142 patients diagnosed with MDS and CMML. AD was ascertained by both the presence of clinical symptoms or compatible serological tests. In total, 48% patients were diagnosed as having AD, being hypothyroidism the most commonly reported clinical AD (8%) and antinuclear antibodies the most frequent serological parameter identified (23.2%). The presence of AD was associated with female gender, lower hemoglobin levels, and higher IPSS-R. Overall survival for patients with AD was inferior to those with no AD (69 vs. 88% at 30 months; HR 2.75, P = 0.008). Notably, clinical but not isolated immune serological parameters had an impact on the outcomes of patients with AD. Finally, in a multivariate analysis, the presence of AD (HR 2.26) along with disease risk categories (very low and low vs. intermediate, high, and very high IPSS-R; HR 4.62) retained their independent prognostic value (P < 0.001). In conclusion, AD are prevalent in MDS and CMML patients and have prognostic implications, especially in lower-risk MDS patients.
Similar content being viewed by others
References
Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361:1872–1885
Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 7:118–129
Haferlach T (2012) Molecular genetics in myelodysplastic syndromes. Leuk Res 36:1459–1462
Foucar K (2009) Myelodysplastic/myeloproliferative neoplasms. Am J Clin Pathol 132(2):281–289
Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G (2015) Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 29(7):1458–1469
Yang L, Qian Y, Eksioglu E, Epling-Burnette PK, Wei S (2015) The inflammatory microenvironment in MDS. Cell Mol Life Sci 72:1959–1966
Fozza C, Crobu V, Isoni MA, Dore F (2016) The immune landscape of myelodysplastic syndromes. Crit Rev Oncol Hematol 107:90–99
Vinh DC, Patel SY, Uzel G, Anderson VL, Freeman AF, Olivier KN, Spalding C, Hughes S, Pittaluga S, Raffeld M, Sorbara LR, Elloumi HZ, Kuhns DB, Turner ML, Cowen EW, Fink D, Long-Priel D, Hsu AP, Ding L, Paulson ML, Whitney AR, Sampaio EP, Frucht DM, DeLeo FR, Holland SM (2010) Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 115(8):1519–1529
Ryu T, Ikeda M, Okazaki Y, Tokuda H, Yoshino N, Honda M, Kimura S, Miura Y (2001) Myelodysplasia associated with acquired immunodeficiency syndrome. Intern Med 40(8):795–801
Dalamaga M, Petridou E, Cook FE, Trichopoulos D (2002) Risk factors for myelodysplastic syndromes: a case-control study in Greece. Cancer Causes Control 13:603–608
Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA (2009) Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 100:822–828
Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf AR, Landgren O, Goldin LR (2011) Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 29:2897–2903
de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Lévesque H, Hamidou M, Subra JF, Ifrah N, Belizna C (2011) Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken) 63:1188–1194
Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK (2016) Autoimmune diseases and myelodysplastic syndromes. Am J Hematol 91:280–283
Okamoto T, Okada M, Mori A, Saheki K, Takatsuka H, Wada H, Tamura A, Fujimori Y, Takemoto Y, Kanamaru A, Kakishita E (1997) Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 66:345–351
Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA (1986) Immunological abnormalities in myelodysplastic syndromes. I Serum immunoglobulins and autoantibodies. Br J Haematol 63:143–147
Sloand EM, Wu CO, Greenberg P, Young N, Barrett J (2008) Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 20 26(15):2505–2511
Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C, Loeliger K, Wu CO, More K, Barrett AJ, Scheinberg P, Young NS (2010) Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 10 28(35):5166–5173
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454–2465
Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419–425
Billstrom R, Johansson H, Johansson B, Mitelman F (1995) Immunemediated complications in patients with myelodysplastic syndromes: clinical and cytogenetic features. Eur J Haematol 55:42–48
Hamblin TJ (1996) Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 33:150–162
Saif MW, Hopkins JL, Gore SD (2002) Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 43:2083–2092
Marisavljević D, Kraguljac N, Rolović Z (2006) Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population. Med Oncol 23:385–391
Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM (2004) Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) 43:626–632
Chaker L, Bianco AC, Jonklaas J, Peeters RP (2017) Hypothyroidism. Lancet 17(6736):4–8
Hamidou MA, Derenne S, Audrain MA, Berthelot JM, Boumalassa A, Grolleau JY (2000) Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. Rheumatology (Oxford) Apr 39(4):417–420
Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA (1997) Range of antinuclear antibodies in Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 40(9):1601–1611
Khan SA, Pruitt SL, Xuan L, Gerber DE (2016) Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol 2:1507–1508
Johnson DB, Sullivan RJ, Ott PA et al (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2:234–240
Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Hamidou M, Park S, Puéchal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, Mathian A, Gombert B, Schoindre Y, Lioger B, De Wazieres B, Amoura Z, Buchdaul AL, Georgin-Lavialle S, Dion J, Madaule S, Raffray L, Cathebras P, Piette JC, Rose C, Ziza JM, Lortholary O, Montestruc F, Omouri M, Denis G, Rossignol J, Nimubona S, Adès L, Gardin C, Fenaux P, Fain O (2016) Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford) 55:291–300
Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W (1995) Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 91(2):403–408
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study was approved by the central ethic committee of the University Hospital Vall d’Hebron, Barcelona, and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Montoro, J., Gallur, L., Merchán, B. et al. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Ann Hematol 97, 1349–1356 (2018). https://doi.org/10.1007/s00277-018-3302-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-018-3302-0